Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence

详细信息    查看全文

• 作者：Alessandro Federico^a ; Marcello Dallio^a ; Justyna Godos^b ; Carmela Loguercio^a ; Federico Salomone^c ; ^{federicosalomone@rocketmail.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：ALT ; alanine aminotransferase ; BMP ; bone morphogenetic protein ; BT ; bacterial translocation ; CFU ; colony-forming unit ; DAMP ; damage associated molecular patterns ; FIAF ; fasting-induced adipose factor ; HSCs ; hepatic stellate cells ; IM ; intestinal microbiota ; IP ; intestinal permeability ; LPS ; lipopolysaccharide ; MetS ; metabolic syndrome ; NAFLD ; nonalcoholic fatty liver disease ; NASH ; ; nonalcoholic steatohepatitis ; NF-kB ; nuclear transcriptional factor kappa-B ; PAMPs ; pathogen-associated molecular
• 刊名：Translational Research
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：167
• 期：1
• 页码：116-124
• 全文大小：296 K

文摘

Nonalcoholic fatty liver disease (NAFLD) is widely emerging as the most prevalent liver disorder and is associated with increased risk of liver-related and cardiovascular mortality. Recent experimental and clinical studies have revealed the pivotal role played by the alteration of gut-liver axis in the onset of fatty liver and related metabolic disturbances. Gut-liver cross talk is implicated not only in the impairment of lipid and glucose homeostasis leading to steatogenesis, but also in the initiation of inflammation and fibrogenesis, which characterize nonalcoholic steatohepatitis (NASH), the evolving form of NAFLD. The gut microbiota has been recognized as the key player in the gut-liver liaison and because of its complexity can act as a villain or a victim. Gut microbiota not only influences absorption and disposal of nutrients to the liver, but also conditions hepatic inflammation by supplying toll-like receptor ligands, which can stimulate liver cells to produce proinflammatory cytokines. Thus, the modification of intestinal bacterial flora by specific probiotics has been proposed as a therapeutic approach for the treatment of NASH. In this review, we summarized the evidence regarding the role of gut-liver axis in the pathogenesis of NASH and discussed the potential therapeutic role of gut microbiota modulation in the clinical setting.